

業績 (筆頭著者のみ)

和文

- 1, 原祐、他. イトラコナゾールのパルス療法により発症した高度の黄疸を伴った薬物性肝障害の1例—本邦および海外におけるイトラコナゾールにおける薬物性肝障害の検討を含めて—. 肝胆膵 63: 849-855, 2011.
- 2, 原祐、他. 高齢者C型慢性肝炎に対するテラプレビル 1500mg 減量投与のパイロット・スタディ. 肝臓 53: 624-626, 2012.
- 3, 原祐、他. 腸内細菌と肝硬変. 肝胆膵 70: 857-861, 2015.
- 4, 原祐、他. 高齢化社会における急性胆嚢炎の治療戦略 ~抗菌薬適正使用を含めた検討~. 京都医学会雑誌 67: 95-100, 2020.
- 5, 原祐、他. 電子カルテネットワークを活用した COVID-19 クラスタに対する支援. 感染症学会雑誌 96: 245-248, 2022.

英文

- 1, Hara T, et al. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol; 85(10): 1746-53, 2013.
- 2, Hara T, et al. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients. J Viral Hepat; 21: 802-8, 2014.
- 3, Hara T, et al. Comparison of the effect of light alcohol consumption on Japanese men with and without fatty liver. Biomed Rep; 11: 191-198, 2019.
- 4, Hara T, et al. Development of Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 21 Years after Achieving a Sustained Virological Response to Interferon Therapy. Case Reports Hepatol: 8824974, 2020.
- 5, Hara T, et al. Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma. Intern Med; 60: 417-421, 2021.

6, Hara T, et al. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. *Intern Med*; 60: 2437-2443, 2021.

7, Hara T, et al. Infection risk in a gastroenterological ward during a nosocomial COVID-19 infection event. *J Med Virol*; 93: 30-31, 2021.

8, Hara T, et al. Microbiological analysis of patients with first and recurrent episodes of acute cholangitis in a middle-sized hospital: A single-center retrospective study in rural North Kyoto, Japan. *J Infect Chemother*; 28: 413-419, 2022.